

Helen Giamarellou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5930743/publications.pdf>

Version: 2024-02-01

304
papers

15,011
citations

14655

66
h-index

27406

106
g-index

306
all docs

306
docs citations

306
times ranked

13940
citing authors

#	ARTICLE	IF	CITATIONS
1	Carbapenemase producing <i>Klebsiella pneumoniae</i> : implication on future therapeutic strategies. Expert Review of Anti-Infective Therapy, 2022, 20, 53-69.	4.4	25
2	Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing <i>Klebsiella pneumoniae</i> of sequence type 39 during treatment. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 219-224.	2.9	26
3	Evolution of epidemiological characteristics of infective endocarditis in Greece. International Journal of Infectious Diseases, 2021, 106, 213-220.	3.3	6
4	Multidrug-resistant <i>Klebsiella pneumoniae</i> : mechanisms of resistance including updated data for novel β -lactam- β -lactamase inhibitor combinations. Expert Review of Anti-Infective Therapy, 2021, 19, 1457-1468.	4.4	28
5	Evaluation of in vitro methods for testing tigecycline combinations against carbapenemase-producing <i>Klebsiella pneumoniae</i> isolates. Journal of Global Antimicrobial Resistance, 2020, 20, 98-104.	2.2	2
6	Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Medicine, 2020, 46, 245-265.	8.2	97
7	Lipid A profiling and metabolomics analysis of paired polymyxin-susceptible and -resistant MDR <i>Klebsiella pneumoniae</i> clinical isolates from the same patients before and after colistin treatment. Journal of Antimicrobial Chemotherapy, 2020, 75, 2852-2863.	3.0	14
8	De-escalation of antimicrobial therapy in ICU settings with high prevalence of multidrug-resistant bacteria: a multicentre prospective observational cohort study in patients with sepsis or septic shock. Journal of Antimicrobial Chemotherapy, 2020, 75, 3665-3674.	3.0	21
9	Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing <i>Klebsiella pneumoniae</i> . Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
10	Carbapenem-Sparing Strategies for ESBL Producers: When and How. Antibiotics, 2020, 9, 61.	3.7	88
11	The Greek study in the effects of colchicine in COVID-19 complications prevention (GRECCO-19 study): Rationale and study design. Hellenic Journal of Cardiology, 2020, 61, 42-45.	1.0	114
12	In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR <i>Pseudomonas aeruginosa</i> isolates from Greece. Journal of Antimicrobial Chemotherapy, 2020, 75, 2164-2172.	3.0	13
13	Outbreak of KPC-2-producing <i>Klebsiella pneumoniae</i> endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019. Eurosurveillance, 2020, 25, .	7.0	31
14	Multifaceted mechanisms of colistin resistance revealed by genomic analysis of multidrug-resistant <i>Klebsiella pneumoniae</i> isolates from individual patients before and after colistin treatment. Journal of Infection, 2019, 79, 312-321.	3.3	24
15	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antimicrobial Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacologists (SIDP). Pharmacotherapy, 2019, 39, 19-33.	2.6	545
16	Nationwide epidemiology of carbapenem resistant <i>Klebsiella pneumoniae</i> isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. BMC Infectious Diseases, 2019, 19, 167.	2.9	68
17	In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing <i>Klebsiella pneumoniae</i> isolated in Greek hospitals in 2015-2016. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1143-1150.	2.9	37
18	Novel β -lactam- β -lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 133-149.	3.3	67

#	ARTICLE	IF	CITATIONS
19	Multifactorial chromosomal variants regulate polymyxin resistance in extensively drug-resistant <i>Klebsiella pneumoniae</i> . <i>Microbial Genomics</i> , 2018, 4, .	2.0	39
20	Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 566-577.	3.1	40
21	Evaluation of ComASP [®] , Colistin (formerly SensiTest [®] , Colistin), a commercial broth microdilution-based method to evaluate the colistin minimum inhibitory concentration for carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates. <i>Journal of Global Antimicrobial Resistance</i> , 2018, 15, 123-126.	2.2	9
22	Epidemiology and resistance phenotypes of carbapenemase-producing <i>Klebsiella pneumoniae</i> in Greece, 2014 to 2016. <i>Eurosurveillance</i> , 2018, 23, .	7.0	59
23	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- β -lactamase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw513.	3.0	46
24	Is there a place for corticosteroids in the therapy of infective endocarditis? Report of a case and review. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 93-95.	1.0	3
25	Mechanisms responsible for imipenem resistance among <i>Pseudomonas aeruginosa</i> clinical isolates exposed to imipenem concentrations within the mutant selection window. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 276-281.	1.8	11
26	Salvage treatment for infections by extensively- and pan-drug-resistant pathogens is common and often sub-optimal. <i>Intensive Care Medicine</i> , 2017, 43, 1164-1166.	8.2	6
27	Reduction of Environmental Contamination With Multidrug-Resistant Bacteria by Copper-Alloy Coating of Surfaces in a Highly Endemic Setting. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 765-771.	1.8	19
28	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 664-672.	2.5	8
29	Combination therapy for extensively-drug resistant gram-negative bacteria. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 1123-1140.	4.4	37
30	Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 98-101.	2.5	31
31	Colistin: still a lifesaver for the 21st century?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 59-71.	3.3	91
32	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. <i>Clinical Infectious Diseases</i> , 2017, 65, 1615-1623.	5.8	43
33	Point-prevalence survey of healthcare facility-onset healthcare-associated <i>Clostridium difficile</i> infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. <i>PLoS ONE</i> , 2017, 12, e0182799.	2.5	8
34	The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardship—results from an international cross-sectional survey. <i>World Journal of Emergency Surgery</i> , 2017, 12, 34.	5.0	47
35	Validated Risk Score for Predicting 6-Month Mortality in Infective Endocarditis. <i>Journal of the American Heart Association</i> , 2016, 5, e003016.	3.7	98
36	A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4159-4169.	3.2	137

#	ARTICLE	IF	CITATIONS
37	Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 337-341.	2.5	28
38	Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). <i>World Journal of Emergency Surgery</i> , 2016, 11, 33.	5.0	130
39	Epidemiology of infections caused by polymyxin-resistant pathogens. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 614-621.	2.5	108
40	Impact of patients' professional and educational status on perception of an antibiotic policy campaign: a pilot study at a university hospital. <i>Journal of Global Antimicrobial Resistance</i> , 2016, 6, 123-127.	2.2	11
41	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1672-1680.	3.0	41
42	Nationwide surveillance of resistance rates of <i>Staphylococcus aureus</i> clinical isolates from Greek hospitals, 2012-2013. <i>Infectious Diseases</i> , 2016, 48, 287-292.	2.8	11
43	Molecular epidemiology of MRSA in 13 ICUs from eight European countries. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 45-52.	3.0	43
44	The Association Between Colonization With Carbapenemase-Producing Enterobacteriaceae and Overall ICU Mortality. <i>Critical Care Medicine</i> , 2015, 43, 1170-1177.	0.9	77
45	Antibacterial Agents. , 2015, , 1345-1359.		1
46	Comparative efficacy of tigecycline VERSUS vancomycin in an experimental model of soft tissue infection by methicillin-resistant <i>Staphylococcus aureus</i> producing Panton-Valentine leukocidin. <i>Journal of Chemotherapy</i> , 2015, 27, 80-86.	1.5	3
47	High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 90-93.	2.5	46
48	Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: a 2014 follow-up survey. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, S1-S14.	2.5	20
49	Survey of metallo- β -lactamase-producing Enterobacteriaceae colonizing patients in European ICUs and rehabilitation units, 2008-11. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1981-1988.	3.0	41
50	Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6471-6476.	3.2	59
51	Plazomicin: an investigational therapy for the treatment of urinary tract infections. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1501-1511.	4.1	35
52	Phylogenetic lineages, clones and β -lactamases in an international collection of <i>Klebsiella oxytoca</i> isolates non-susceptible to expanded-spectrum cephalosporins. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv273.	3.0	24
53	Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7240-7248.	3.2	93
54	MLST reveals potentially high-risk international clones of <i>Enterobacter cloacae</i> *. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 48-56.	3.0	131

#	ARTICLE	IF	CITATIONS
55	Infections caused by carbapenem-resistant <i>Klebsiella pneumoniae</i> among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. <i>Clinical Microbiology and Infection</i> , 2014, 20, O117-O123.	6.0	138
56	Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 31-39.	9.1	297
57	Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 52-59.	2.5	188
58	Large vessel vasculitis in a patient with acute Q-fever: A case report. <i>IDCases</i> , 2014, 1, 56-59.	0.9	14
59	Promoting prudent use of antibiotics: the experience from a multifaceted regional campaign in Greece. <i>BMC Public Health</i> , 2014, 14, 866.	2.9	23
60	Is there a future for tigecycline?. <i>Intensive Care Medicine</i> , 2014, 40, 1039-1045.	8.2	21
61	Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1351-1370.	1.8	259
62	In vivo transmission of a plasmid containing the KPC-2 gene in a single patient. <i>Journal of Global Antimicrobial Resistance</i> , 2013, 1, 35-38.	2.2	2
63	Impact of a hospital-wide antibiotic restriction policy program on the resistance rates of nosocomial Gram-negative bacteria. <i>Scandinavian Journal of Infectious Diseases</i> , 2013, 45, 438-445.	1.5	16
64	Nosocomial dissemination of <i>Providencia stuartii</i> isolates producing extended-spectrum β -lactamases VEB-1 and SHV-5, metallo- β -lactamase VIM-1, and RNA methylase RmtB. <i>Journal of Global Antimicrobial Resistance</i> , 2013, 1, 115-116.	2.2	9
65	Polymicrobial bloodstream infections: Epidemiology and impact on mortality. <i>Journal of Global Antimicrobial Resistance</i> , 2013, 1, 207-212.	2.2	43
66	Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2388-2390.	3.2	115
67	Successful treatment of extensively drug-resistant <i>Acinetobacter baumannii</i> ventriculitis and meningitis with intraventricular colistin after application of a loading dose: a case series. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 480-483.	2.5	44
68	Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant <i>Acinetobacter baumannii</i> ventriculitis and meningitis: a literature review. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 499-508.	2.5	133
69	The impact of an antimicrobial cycling strategy for febrile neutropenia in a haematology unit. <i>Journal of Chemotherapy</i> , 2013, 25, 279-285.	1.5	5
70	Antimicrobial activity of copper surfaces against carbapenemase-producing contemporary Gram-negative clinical isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 852-857.	3.0	49
71	Efficacy of Tigecycline Alone and in Combination with Gentamicin in the Treatment of Experimental Endocarditis Due to Linezolid-Resistant <i>Enterococcus faecium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3392-3394.	3.2	11
72	Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 668-671.	3.2	71

#	ARTICLE	IF	CITATIONS
73	Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β -lactamase-producing <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2424-2428.	3.0	39
74	Activity of Plazomicin (ACHN-490) against MDR clinical isolates of <i>Klebsiella pneumoniae</i> , <i>Escherichia coli</i> , and <i>Enterobacter</i> spp. from Athens, Greece. <i>Journal of Chemotherapy</i> , 2012, 24, 191-194.	1.5	84
75	Prevalence of 16S rRNA methylase genes in Enterobacteriaceae isolates from a Greek University Hospital. <i>Clinical Microbiology and Infection</i> , 2012, 18, E52-E54.	6.0	35
76	Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients. <i>BMC Infectious Diseases</i> , 2012, 12, 228.	2.9	9
77	Long-term triple-antibiotic treatment against brucellar vertebral osteomyelitis. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 91-93.	2.5	5
78	Application of a Loading Dose of Colistin Methanesulfonate in Critically Ill Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4241-4249.	3.2	201
79	Evaluation of CHROMagar [®] , [†] KPC for the detection of carbapenemase-producing Enterobacteriaceae in rectal surveillance cultures. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 124-128.	2.5	46
80	Comparison of direct antimicrobial susceptibility testing methods for rapid analysis of bronchial secretion samples in ventilator-associated pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 130-134.	2.5	13
81	Glycopeptide and daptomycin susceptibility and vancomycin heteroresistance of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) clinical isolates from a Greek university hospital. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 451-452.	2.5	3
82	Epidemiology and molecular characterisation of metallo- β -lactamase-producing Enterobacteriaceae in a university hospital Intensive Care Unit in Greece. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 390-397.	2.5	23
83	Pharmacokinetic and pharmacodynamic evaluation of tigecycline. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1459-1470.	3.3	59
84	Metallo- β -lactamases: a last frontier for β -lactams?. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 381-393.	9.1	562
85	The value of successive Infecton scans in assessing the presence of chronic bone and joint infection and in predicting its evolution after treatment and after a prolonged follow-up. <i>Nuclear Medicine Communications</i> , 2011, 32, 1060-1069.	1.1	10
86	Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. <i>Clinical Microbiology and Infection</i> , 2011, 17, E9-E11.	6.0	86
87	Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. <i>Journal of Critical Care</i> , 2011, 26, 331.e1-331.e7.	2.2	44
88	When and How to Cover for Resistant Gram-Negative Bacilli in Severe Sepsis and Septic Shock. <i>Current Infectious Disease Reports</i> , 2011, 13, 416-425.	3.0	9
89	European Surveillance of Antimicrobial Consumption (ESAC): systemic antiviral use in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1897-1905.	3.0	94
90	Efficacy of carbapenems against a metallo- β -lactamase-producing <i>Escherichia coli</i> clinical isolate in a rabbit intra-abdominal abscess model. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 611-617.	3.0	20

#	ARTICLE	IF	CITATIONS
91	<i>In Vitro</i> Interactions of Antimicrobial Combinations with Fosfomycin against KPC-2-Producing <i>Klebsiella pneumoniae</i> and Protection of Resistance Development. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2395-2397.	3.2	97
92	Successful virological outcome in an HIV-infected individual with a three-class resistant variant and an insertion in the protease genome with a Tipranavir based regimen. <i>Irish Journal of Medical Science</i> , 2010, 179, 305-307.	1.5	0
93	Carbapenem-resistant versus carbapenem-susceptible <i>Acinetobacter baumannii</i> bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. <i>Infection</i> , 2010, 38, 173-180.	4.7	66
94	<i>In vitro</i> elution of moxifloxacin from cancellous bone allografts. <i>Journal of Biomedical Materials Research - Part A</i> , 2010, 92A, 52-55.	4.0	4
95	Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. <i>BMC Infectious Diseases</i> , 2010, 10, 286.	2.9	22
96	Ampicillin/Sulbactam versus Cefuroxime as antimicrobial prophylaxis for cesarean delivery: a randomized study. <i>BMC Infectious Diseases</i> , 2010, 10, 341.	2.9	19
97	Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. <i>Clinical Microbiology and Infection</i> , 2010, 16, 102-111.	6.0	216
98	Microcirculatory Vascular Dysfunction in HIV-1 Infected Patients Receiving Highly Active Antiretroviral Therapy. <i>Microcirculation</i> , 2010, 17, 303-310.	1.8	8
99	Development of standardized methods for analysis of changes in antibacterial use in hospitals from 18 European countries: the European Surveillance of Antimicrobial Consumption (ESAC) longitudinal survey, 2000-06. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2685-2691.	3.0	22
100	Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 62-67.	2.5	30
101	Contemporary trends in susceptibilities to older and new antimicrobial agents of clinical <i>Staphylococcus aureus</i> isolates from a Greek University Hospital. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 187-189.	2.5	3
102	Presence of plasmid-mediated quinolone resistance in <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> isolates possessing bla _{VIM-1} in Greece. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 252-254.	2.5	19
103	Multidrug-resistant Gram-negative bacteria: how to treat and for how long. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, S50-S54.	2.5	129
104	Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. <i>Critical Care</i> , 2010, 14, R96.	5.8	109
105	An Outbreak of Infection due to β -Lactamase-producing <i>Klebsiella pneumoniae</i> Carbapenemase-producing <i>K. pneumoniae</i> in a Greek University Hospital: Molecular Characterization, Epidemiology, and Outcomes. <i>Clinical Infectious Diseases</i> , 2010, 50, 364-373.	5.8	251
106	Discrepancies between Various Methods in Susceptibility Testing and Epidemiological Analysis of <i>Stenotrophomonas maltophilia</i> Clinical Isolates. <i>Central European Journal of Public Health</i> , 2010, 18, 119-123.	1.1	8
107	Comment on: Redefining extended-spectrum β -lactamases: balancing science and clinical need. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 212-213.	3.0	18
108	Does the Activity of the Combination of Imipenem and Colistin <i>In Vitro</i> Exceed the Problem of Resistance in Metallo- β -Lactamase-Producing <i>Klebsiella pneumoniae</i> Isolates?. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2133-2135.	3.2	56

#	ARTICLE	IF	CITATIONS
109	Association of Highly Active Antiretroviral Therapy With Increased Arterial Stiffness in Patients Infected With Human Immunodeficiency Virus. <i>American Journal of Hypertension</i> , 2009, 22, 828-834.	2.0	49
110	Bacterial flora in residents of long-term care facilities: a point prevalence study. <i>Journal of Hospital Infection</i> , 2009, 71, 385-387.	2.9	6
111	Risk factors for nasopharyngeal carriage of drug-resistant <i>Streptococcus pneumoniae</i> : data from a nation-wide surveillance study in Greece. <i>BMC Infectious Diseases</i> , 2009, 9, 120.	2.9	30
112	Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. <i>BMC Infectious Diseases</i> , 2009, 9, 213.	2.9	47
113	Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. <i>Journal of Infection</i> , 2009, 58, 273-284.	3.3	95
114	Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3430-3436.	3.2	448
115	Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study. <i>Critical Care</i> , 2009, 13, R172.	5.8	34
116	Does a bed rail system of alcohol-based handrub antiseptic improve compliance of health care workers with hand hygiene? Results from a pilot study. <i>American Journal of Infection Control</i> , 2009, 37, 160-163.	2.3	17
117	Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 65-69.	2.5	5
118	Colonisation with vancomycin- and linezolid-resistant <i>Enterococcus faecium</i> in a university hospital: molecular epidemiology and risk factor analysis. <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 137-142.	2.5	27
119	Treatment of experimental osteomyelitis caused by methicillin-resistant <i>Staphylococcus aureus</i> with a synthetic carrier of calcium sulphate (Stimulan®) releasing moxifloxacin. <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 354-359.	2.5	60
120	Efficacy of teicoplanin for the prevention of surgical site infections after total hip or knee arthroplasty: a prospective, open-label study. <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 437-440.	2.5	28
121	Multidrug-Resistant Gram-Negative Infections. <i>Drugs</i> , 2009, 69, 1879-1901.	10.9	237
122	Health Care-Associated Native Valve Endocarditis: Importance of Non-nosocomial Acquisition. <i>Annals of Internal Medicine</i> , 2009, 150, 586.	3.9	224
123	Effect of the Novel Influenza A (H1N1) Virus in the Human Immune System. <i>PLoS ONE</i> , 2009, 4, e8393.	2.5	62
124	An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2008, 158, 567-572.	1.5	109
125	Screening for resistant gram-negative microorganisms to guide empiric therapy of subsequent infection. <i>Intensive Care Medicine</i> , 2008, 34, 2169-75.	8.2	55
126	Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci. <i>Clinical Microbiology and Infection</i> , 2008, 14, 14-21.	6.0	72

#	ARTICLE	IF	CITATIONS
127	Current Therapies for Pseudomonas Aeruginosa. Critical Care Clinics, 2008, 24, 261-278.	2.6	39
128	Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens. Expert Opinion on Investigational Drugs, 2008, 17, 749-771.	4.1	18
129	Colistin susceptibility testing by Etest and disk diffusion methods. International Journal of Antimicrobial Agents, 2008, 31, 434-439.	2.5	120
130	Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. International Journal of Antimicrobial Agents, 2008, 32, 46-49.	2.5	17
131	Acinetobacter baumannii: a universal threat to public health?. International Journal of Antimicrobial Agents, 2008, 32, 106-119.	2.5	185
132	In vitro synergism of β -lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2008, 32, 33-39.	2.5	17
133	In vitro elution of moxifloxacin and fusidic acid by a synthetic crystalline semihydrate form of calcium sulphate (Stimulan [®] , Φ). International Journal of Antimicrobial Agents, 2008, 32, 485-487.	2.5	21
134	Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. Journal of Antimicrobial Chemotherapy, 2008, 61, 1328-1331.	3.0	47
135	Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis. Journal of Antimicrobial Chemotherapy, 2008, 62, 381-383.	3.0	29
136	Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens. Expert Opinion on Investigational Drugs, 2008, 17, 225-243.	4.1	39
137	Evaluation of different laboratory tests for the detection of metallo- β -lactamase production in Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2008, 61, 548-553.	3.0	107
138	Local Treatment of Experimental Pseudomonas aeruginosa Osteomyelitis with a Biodegradable Dilactide Polymer Releasing Ciprofloxacin. Antimicrobial Agents and Chemotherapy, 2008, 52, 2335-2339.	3.2	19
139	Effect of Clarithromycin in Patients with Sepsis and Ventilator-Associated Pneumonia. Clinical Infectious Diseases, 2008, 46, 1157-1164.	5.8	227
140	Clinical Experience of Serious Infections Caused by Enterobacteriaceae Producing VIM-1 Metallo- β -Lactamase in a Greek University Hospital. Clinical Infectious Diseases, 2008, 46, 847-854.	5.8	95
141	Evaluation of a rapid antigen detection test in the diagnosis of streptococcal pharyngitis in children and its impact on antibiotic prescription. Journal of Antimicrobial Chemotherapy, 2008, 62, 1407-1412.	3.0	62
142	The impact on community acquired pneumonia empirical therapy of diagnostic bronchoscopic techniques. Scandinavian Journal of Infectious Diseases, 2008, 40, 286-292.	1.5	14
143	HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease. Clinical Science, 2008, 115, 189-196.	4.3	39
144	Emerging bacterial pathogens: Escherichia coli, Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring the same transferable plasmid coding for metallo- β -lactamase VIM-1 in Greece. Journal of Antimicrobial Chemotherapy, 2007, 59, 578-579.	3.0	25

#	ARTICLE	IF	CITATIONS
145	Hospital-acquired pneumonia guidelines in Europe: a review of their status and future development. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 206-213.	3.0	37
146	Investigational treatments for postoperative surgical site infections. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 137-155.	4.1	20
147	Colistin-resistant isolates of <i>Klebsiella pneumoniae</i> emerging in intensive care unit patients: first report of a multiclonal cluster. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 786-790.	3.0	224
148	Dexamethasone as Adjuvant Therapy to Moxifloxacin Attenuates Valve Destruction in Experimental Aortic Valve Endocarditis Due to <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2848-2854.	3.2	6
149	In vitro postantibiotic effect of colistin on multidrug-resistant <i>Acinetobacter baumannii</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 419-422.	1.8	32
150	Fever of Unknown Origin in Febrile Leukopenia. <i>Infectious Disease Clinics of North America</i> , 2007, 21, 1055-1090.	5.1	32
151	Colistin offers prolonged survival in experimental infection by multidrug-resistant <i>Acinetobacter baumannii</i> : the significance of co-administration of rifampicin. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 51-55.	2.5	77
152	Metallo- β -lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 380-388.	2.5	134
153	Detection of CTX-M-15 and CTX-M-33, a novel variant of CTX-M-15, in clinical <i>Escherichia coli</i> isolates in Greece. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 598-600.	2.5	10
154	The significance of compliance for the success of antimicrobial prophylaxis in recurrent lower urinary tract infections: the Greek experience. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 40-43.	2.5	13
155	Nationwide surveillance of <i>Streptococcus pneumoniae</i> in Greece: patterns of resistance and serotype epidemiology. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 87-92.	2.5	26
156	Impact of an antibiotic restriction policy on the antibiotic resistance patterns of Gram-negative microorganisms in an Intensive Care Unit in Greece. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 360-365.	2.5	56
157	Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2007, 156, 51-56.	1.5	118
158	Early apoptosis of blood monocytes is a determinant of survival in experimental sepsis by multi-drug-resistant <i>Pseudomonas aeruginosa</i> . <i>Clinical and Experimental Immunology</i> , 2007, 149, 103-108.	2.6	11
159	Characterisation of macrolide-non-susceptible <i>Streptococcus pneumoniae</i> colonising children attending day-care centres in Athens, Greece during 2000 and 2003. <i>Clinical Microbiology and Infection</i> , 2007, 13, 70-77.	6.0	5
160	Nosocomial vs. community-acquired infective endocarditis in Greece: changing epidemiological profile and mortality risk. <i>Clinical Microbiology and Infection</i> , 2007, 13, 763-769.	6.0	62
161	Can Soluble Triggering Receptor Expressed on Myeloid Cells (sTREM-1) Be Considered an Anti-Inflammatory Mediator in the Pathogenesis of Peptic Ulcer Disease?. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2166-2169.	2.3	10
162	Evidence for the role of gastric mucosa at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in peptic ulcer disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 4610.	3.3	4

#	ARTICLE	IF	CITATIONS
163	Fever of Unknown Origin in Febrile Leukopenia. <i>Infectious Disease and Therapy</i> , 2007, , 35-58.	0.0	0
164	Monocytes as a site of production of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in the septic host. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 909-915.	1.5	3
165	Treatment options for multidrug-resistant bacteria. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 601-618.	4.4	71
166	Factors Affecting the Increased Prevalence of Erectile Dysfunction in Greek Hypertensive Compared With Normotensive Subjects. <i>Journal of Andrology</i> , 2006, 27, 469-477.	2.0	119
167	Community-acquired methicillin-resistant <i>Staphylococcus aureus</i> infections. <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 87-96.	2.5	152
168	Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 476-481.	2.5	44
169	Comparative elution of moxifloxacin from Norian skeletal repair system and acrylic bone cement: an in vitro study. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 217-220.	2.5	15
170	Evolution of resistance patterns and identification of risk factors for <i>Streptococcus pneumoniae</i> colonisation in daycare centre attendees in Athens, Greece. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 297-301.	2.5	11
171	Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock?. <i>Critical Care</i> , 2006, 10, R76.	5.8	47
172	Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. <i>Critical Care</i> , 2006, 10, R166.	5.8	67
173	An update on the etiology and diagnostic evaluation of a leukemoid reaction. <i>European Journal of Internal Medicine</i> , 2006, 17, 394-398.	2.2	94
174	Portal and Systemic Endotoxemia in Abdominal Operations: The Significance of Acute Abdomen. <i>Journal of Surgical Research</i> , 2006, 134, 133-137.	1.6	7
175	Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2006, 12, 3416.	3.3	63
176	Is There Any Role for Innate Immunity in the Pathogenesis of Bacterial and Abacterial Meningitis?. <i>Infectious Diseases in Clinical Practice</i> , 2006, 14, 17-22.	0.3	0
177	Soluble triggering receptor expressed on myeloid cells (sTREM-1): a new mediator involved in the pathogenesis of peptic ulcer disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 375-379.	1.6	38
178	The Value of Chemoprophylaxis Against <i>Enterococcus</i> Species in Elective Cholecystectomy. <i>Archives of Surgery</i> , 2006, 141, 1162.	2.2	33
179	Female sexual dysfunction in essential hypertension: a common problem being uncovered. <i>Journal of Hypertension</i> , 2006, 24, 2387-2392.	0.5	126
180	OLEUROPEIN. <i>Shock</i> , 2006, 26, 410-416.	2.1	37

#	ARTICLE	IF	CITATIONS
181	Kinetics of progenitor hemopoetic stem cells in sepsis: Correlation with patients survival?. BMC Infectious Diseases, 2006, 6, 142.	2.9	18
182	Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant <i>Pseudomonas aeruginosa</i> . BMC Infectious Diseases, 2006, 6, 31.	2.9	24
183	Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavirâ€“ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors. Clinical Microbiology and Infection, 2006, 12, 486-489.	6.0	8
184	<i>Mycoplasma pneumoniae</i> -associated myelitis: a comprehensive review. European Journal of Neurology, 2006, 13, 112-124.	3.3	79
185	Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian Journal of Andrology, 2006, 8, 177-182.	1.6	85
186	Early apoptosis of monocytes contributes to the pathogenesis of systemic inflammatory response and of bacterial translocation in an experimental model of multiple trauma. Clinical and Experimental Immunology, 2006, 145, 139-146.	2.6	16
187	Soluble triggering receptor expressed on myeloid cells 1 as an anti-inflammatory mediator in sepsis. Intensive Care Medicine, 2006, 32, 237-243.	8.2	72
188	Linezolid in Prophylaxis against Experimental Aortic Valve Endocarditis Due to <i>Streptococcus oralis</i> or <i>Enterococcus faecalis</i> . Antimicrobial Agents and Chemotherapy, 2006, 50, 654-657.	3.2	9
189	In Vitro Activity of Tigecycline against Multiple-Drug-Resistant, Including Pan-Resistant, Gram-Negative and Gram-Positive Clinical Isolates from Greek Hospitals. Antimicrobial Agents and Chemotherapy, 2006, 50, 3166-3169.	3.2	91
190	Molecular characterization of an <i>Escherichia coli</i> clinical isolate that produces both metallo-Â-lactamase VIM-2 and extended-spectrum Â-lactamase GES-7: identification of the In8 integron carrying the blaVIM-2 gene. Journal of Antimicrobial Chemotherapy, 2006, 58, 432-433.	3.0	11
191	Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant <i>Klebsiella pneumoniae</i> . Journal of Antimicrobial Chemotherapy, 2006, 57, 937-944.	3.0	44
192	Central nervous system manifestations of <i>Mycoplasma pneumoniae</i> infections. Journal of Infection, 2005, 51, 343-354.	3.3	162
193	Does soluble triggering receptor expressed on myeloid cells-1 play any role in the pathogenesis of septic shock?. Clinical and Experimental Immunology, 2005, 142, 62-67.	2.6	49
194	Immunomodulatory intervention in sepsis by multidrug-resistant <i>Pseudomonas aeruginosa</i> with thalidomide: an experimental study. BMC Infectious Diseases, 2005, 5, 51.	2.9	16
195	Penetration of moxifloxacin into the human aqueous humour after oral administration. British Journal of Ophthalmology, 2005, 89, 628-631.	3.9	40
196	Characterization of a new integron containing blaVIM-1 and aac(6â€“IIc) in an <i>Enterobacter cloacae</i> clinical isolate from Greece. Journal of Antimicrobial Chemotherapy, 2005, 55, 634-638.	3.0	47
197	Septic arthritis due to <i>Salmonella enteritidis</i> associated with infliximab use. Scandinavian Journal of Infectious Diseases, 2005, 37, 304-306.	1.5	45
198	Successful moxifloxacin prophylaxis against experimental streptococcal aortic valve endocarditis. Journal of Antimicrobial Chemotherapy, 2005, 56, 1160-1162.	3.0	4

#	ARTICLE	IF	CITATIONS
199	Clarithromycin: Immunomodulatory therapy of experimental sepsis and acute pyelonephritis by <i>Escherichia coli</i> . <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 48-54.	1.5	24
200	Cholestatic liver injury after glimepiride therapy. <i>Journal of Hepatology</i> , 2005, 42, 944-946.	3.7	34
201	Postantibiotic effect of antimicrobial combinations on multidrug-resistant <i>Pseudomonas aeruginosa</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 51, 113-117.	1.8	23
202	The significance of oxidant/antioxidant balance for the pathogenesis of experimental sepsis by multidrug-resistant <i>Pseudomonas aeruginosa</i> . <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2005, 72, 41-47.	2.2	4
203	Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with <i>Escherichia coli</i> . <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 168-172.	2.5	30
204	Immunomodulatory Clarithromycin Treatment of Experimental Sepsis and Acute Pyelonephritis Caused by Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 93-99.	3.2	78
205	n-6 Polyunsaturated Fatty Acids Enhance the Activities of Ceftazidime and Amikacin in Experimental Sepsis Caused by Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4713-4717.	3.2	19
206	Stimulation of innate immunity by susceptible and multidrug-resistant <i>Pseudomonas aeruginosa</i> : an <i>in vitro</i> and <i>in vivo</i> study. <i>Clinical and Experimental Immunology</i> , 2004, 135, 240-246.	2.6	41
207	Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. <i>Clinical Microbiology and Infection</i> , 2004, 10, 628-633.	6.0	76
208	First identification of an <i>Escherichia coli</i> clinical isolate producing both metallo- β -lactamase VIM-2 and extended-spectrum β -lactamase IBC-1. <i>Clinical Microbiology and Infection</i> , 2004, 10, 757-760.	6.0	35
209	Should procalcitonin be introduced in the diagnostic criteria for the systemic inflammatory response syndrome and sepsis?. <i>Journal of Critical Care</i> , 2004, 19, 152-157.	2.2	51
210	Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 144-149.	2.5	23
211	The influence of indomethacin co-administration on ofloxacin levels in plasma and cerebrospinal fluid in rats. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 371-376.	2.5	2
212	Experimental sepsis using <i>Pseudomonas aeruginosa</i> : the significance of multi-drug resistance. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 357-361.	2.5	17
213	Rapid alterations of serum fatty acids with the intravenous administration of an arachidonate solution. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2004, 70, 465-468.	2.2	4
214	Lipid peroxidation and inguinal hernia repair. Tension-free vs. Andrews technique. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2004, 71, 221-225.	2.2	3
215	Infecton: a ^{99m}Tc -ciprofloxacin radiopharmaceutical for the detection of bone infection. <i>Clinical Microbiology and Infection</i> , 2003, 9, 101-109.	6.0	44
216	Are There Regional Variations in the Diagnosis, Surveillance, and Control of Methicillin-Resistant <i>Staphylococcus aureus</i> ?. <i>Infection Control and Hospital Epidemiology</i> , 2003, 24, 334-341.	1.8	34

#	ARTICLE	IF	CITATIONS
217	Systemic endotoxaemia following obstructive jaundice: the role of lactulose. <i>Journal of Surgical Research</i> , 2003, 113, 243-247.	1.6	29
218	Ex vivo synergy of arachidonate-enriched serum with ceftazidime and amikacin on multidrug-resistant <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 423-426.	3.0	4
219	Effective Immunomodulatory Treatment of <i>Escherichia coli</i> Experimental Sepsis with Thalidomide. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2445-2449.	3.2	15
220	Influence of population density on antibiotic resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 385-390.	3.0	70
221	Cefpodoxime-Proxetil versus Trimethoprim-Sulfamethoxazole for Short-Term Therapy of Uncomplicated Acute Cystitis in Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 897-900.	3.2	65
222	Pharmacokinetics of Teicoplanin in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2003, 23, 127-131.	2.3	23
223	The role of fluoroquinolones in the therapy and prophylaxis of neutropenic patients with cancer. <i>Milestones in Drug Therapy</i> , 2003, , 219-238.	0.1	0
224	Pharmacokinetics of teicoplanin in patients undergoing continuous ambulatory peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2003, 23, 127-31.	2.3	31
225	In Vitro Killing Effect of Moxifloxacin on Clinical Isolates of <i>Stenotrophomonas maltophilia</i> Resistant to Trimethoprim-Sulfamethoxazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3997-3999.	3.2	20
226	Prescribing guidelines for severe <i>Pseudomonas</i> infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 229-233.	3.0	73
227	Pharmacokinetics of teicoplanin in patients undergoing chronic haemodialysis. <i>International Journal of Antimicrobial Agents</i> , 2002, 19, 233-236.	2.5	17
228	Bacterial translocation following intrabdominal surgery. Any influence of antimicrobial prophylaxis?. <i>International Journal of Antimicrobial Agents</i> , 2002, 20, 457-460.	2.5	21
229	Nosocomial cardiac infections. <i>Journal of Hospital Infection</i> , 2002, 50, 91-105.	2.9	91
230	Routine surface disinfection in health care facilities: Should we do it?. <i>American Journal of Infection Control</i> , 2002, 30, 318-319.	2.3	27
231	Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant <i>Stenotrophomonas maltophilia</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 44, 259-263.	1.8	52
232	Transferable plasmid mediating resistance to multiple antimicrobial agents in <i>Klebsiella pneumoniae</i> isolates in Greece. <i>Clinical Microbiology and Infection</i> , 2002, 8, 579-588.	6.0	20
233	Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient?. <i>Intensive Care Medicine</i> , 2002, 28, 1351-1356.	8.2	137
234	Pharmacokinetics of intravenously administered pefloxacin in the prostate; perspectives for its application in surgical prophylaxis. <i>International Journal of Antimicrobial Agents</i> , 2001, 17, 221-224.	2.5	3

#	ARTICLE	IF	CITATIONS
235	Classification of oral cephalosporins. A matter for debate. <i>International Journal of Antimicrobial Agents</i> , 2001, 17, 443-450.	2.5	16
236	Vancomycin levels in human aqueous humour after intravenous and subconjunctival administration. <i>International Journal of Antimicrobial Agents</i> , 2001, 18, 239-243.	2.5	23
237	Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. <i>International Journal of Antimicrobial Agents</i> , 2001, 18, 441-444.	2.5	16
238	Interactions of colistin and rifampin on multidrug-resistant <i>Acinetobacter baumannii</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2001, 40, 117-120.	1.8	124
239	ANTIPSEUDOMONAL ANTIBIOTICS. <i>Medical Clinics of North America</i> , 2001, 85, 19-42.	2.5	46
240	INFECTIOUS COMPLICATIONS OF FEBRILE LEUKOPENIA. <i>Infectious Disease Clinics of North America</i> , 2001, 15, 457-482.	5.1	34
241	Evidence of Less Severe Aortic Valve Destruction after Treatment of Experimental Staphylococcal Endocarditis with Vancomycin and Dexamethasone. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 3531-3537.	3.2	13
242	The effect of acetazolamide on the kinetics of four newer β -lactams in the aqueous humor. <i>Clinical Microbiology and Infection</i> , 2001, 7, 70-74.	6.0	4
243	In Vitro Activities of Ertapenem (MK-0826) against Recent Clinical Bacteria Collected in Europe and Australia. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1860-1867.	3.2	122
244	Assessment of Procalcitonin as a Diagnostic Marker of Underlying Infection in Patients with Febrile Neutropenia. <i>Clinical Infectious Diseases</i> , 2001, 32, 1718-1725.	5.8	94
245	Successful Trovafloxacin Prophylaxis against Experimental Streptococcal Aortic Valve Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2564-2566.	3.2	3
246	Impact of n-6 Polyunsaturated Fatty Acids on Growth of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> : Interactions with Amikacin and Ceftazidime. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2187-2189.	3.2	17
247	Treatment of experimental osteomyelitis caused by methicillin-resistant <i>Staphylococcus aureus</i> with a biodegradable system of lactic acid polymer releasing pefloxacin. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 46, 311-314.	3.0	39
248	Single-Oral-Dose Azithromycin Prophylaxis against Experimental Streptococcal or Staphylococcal Aortic Valve Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1754-1756.	3.2	5
249	Monotherapy with Intravenous Followed by Oral High-Dose Ciprofloxacin versus Combination Therapy with Ceftazidime plus Amikacin as Initial Empiric Therapy for Granulocytopenic Patients with Fever. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 3264-3271.	3.2	56
250	In-vitro activity of FK 037 (Cefoselis), a novel 4th generation Cephalosporin, compared to Cefepime and Cefpirome on nosocomial staphylococci and gram-negative isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2000, 36, 185-191.	1.8	13
251	AIDS and the skin: parasitic diseases. <i>Clinics in Dermatology</i> , 2000, 18, 433-439.	1.6	4
252	Therapeutic guidelines for <i>Pseudomonas aeruginosa</i> infections. <i>International Journal of Antimicrobial Agents</i> , 2000, 16, 103-106.	2.5	47

#	ARTICLE	IF	CITATIONS
253	Anaerobic infection therapy. <i>International Journal of Antimicrobial Agents</i> , 2000, 16, 341-346.	2.5	20
254	Lactic Acid Polymers as Biodegradable Carriers of Fluoroquinolones: An In Vitro Study. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 714-716.	3.2	50
255	Visceral Leishmaniasis in Renal Transplant Recipients: Successful Treatment with Liposomal Amphotericin B (AmBisome). <i>Clinical Infectious Diseases</i> , 1999, 28, 1308-1309.	5.8	34
256	Comparative Postantibiotic Effect of Sitafloxacin and Trovafloxacin on Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Drugs</i> , 1999, 58, 146-148.	10.9	1
257	Sitafloxacin (DU-6859a) and trovafloxacin: postantibiotic effect and in vitro interactions with rifampin on methicillin-resistant <i>Staphylococcus aureus</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 1999, 34, 301-307.	1.8	9
258	Gatifloxacin. <i>Drugs</i> , 1999, 58, 697-698.	10.9	1
259	Impact of cefuroxime administration on endotoxin (LPS) and tumour necrosis factor- α (TNF α) blood levels in patients suffering from acute pyelonephritis: a preliminary report. <i>International Journal of Antimicrobial Agents</i> , 1999, 11, 115-119.	2.5	16
260	Asymptomatic Bacteriuria in Freely Voiding Elderly Subjects. <i>Clinical Drug Investigation</i> , 1998, 15, 187-195.	2.2	8
261	Interactions of Ceftazidime and Amikacin on Multiresistant <i>Pseudomonas aeruginosa</i> . <i>Clinical Drug Investigation</i> , 1998, 16, 167-171.	2.2	1
262	In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial <i>Staphylococcus aureus</i> and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 1998, 41, 349-355.	3.0	27
263	Effects of Slime Produced by Clinical Isolates of Coagulase-Negative Staphylococci on Activities of Various Antimicrobial Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 939-941.	3.2	86
264	Chronic osteomyelitis caused by multi-resistant Gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 39, 241-246.	3.0	54
265	Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant <i>Pseudomonas aeruginosa</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 1997, 29, 81-86.	1.8	27
266	Bacteriologic and Therapeutic Considerations in Intra-abdominal Surgical Infections. <i>Anaerobe</i> , 1997, 3, 207-212.	2.1	7
267	The Effect of Monitoring of Antibiotic use on Decreasing Antibiotic Resistance in the Hospital. <i>Novartis Foundation Symposium</i> , 1997, 207, 76-92.	1.1	12
268	Ciprofloxacin and imipenem alone or in combination in experimental aortic valve endocarditis due to a ciprofloxacin borderline susceptible strain of <i>Pseudomonas aeruginosa</i> . <i>International Journal of Antimicrobial Agents</i> , 1996, 7, 23-28.	2.5	1
269	Non-aeruginosa pseudomonads: Infection and treatment. <i>Current Opinion in Infectious Diseases</i> , 1996, 9, 385-390.	3.1	0
270	Epidemiology, Diagnosis, and Therapy of Fungal Infections in Surgery. <i>Infection Control and Hospital Epidemiology</i> , 1996, 17, 558-564.	1.8	8

#	ARTICLE	IF	CITATIONS
271	Epidemiology, Diagnosis, and Therapy of Fungal Infections in Surgery. <i>Infection Control and Hospital Epidemiology</i> , 1996, 17, 558-564.	1.8	28
272	Empiric therapy for infections in the febrile, neutropenic, compromised host. <i>Medical Clinics of North America</i> , 1995, 79, 559-580.	2.5	20
273	Pharmacokinetic study of fibrin clot-ciprofloxacin complex: an in vitro and in vivo experimental investigation. <i>Archives of Orthopaedic and Trauma Surgery</i> , 1995, 114, 295-297.	2.4	30
274	Regional intravenous versus systemic intravenous prophylactic administration of third-generation cephalosporins (ceftazidime and ceftriaxone) in elective foot surgery. <i>Foot</i> , 1995, 5, 133-136.	1.1	3
275	In-vitro inhibitory activity of gamma-linolenic acid on <i>Escherichia coli</i> strains and its influence on their susceptibilities to various antimicrobial agents. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 36, 327-334.	3.0	13
276	In vitro influence of polyunsaturated fatty acids on nosocomial <i>Pseudomonas aeruginosa</i> : a preliminary report. <i>International Journal of Antimicrobial Agents</i> , 1995, 6, 47-50.	2.5	5
277	Activity of Quinolones against Gram-Positive Cocci. <i>Drugs</i> , 1995, 49, 58-66.	10.9	16
278	Comparative In Vitro Activity of Ciprofloxacin vs 8 Antimicrobial Agents against Nosocomial Multiresistant <i>P. aeruginosa</i> Strains. <i>Drugs</i> , 1995, 49, 203-204.	10.9	2
279	Periareolar Nonpuerperal Breast Infection: Treatment of 38 Cases. <i>Clinical Infectious Diseases</i> , 1994, 18, 73-76.	5.8	32
280	Proposed study design in prostatitis. <i>Infection</i> , 1994, 22, S59-S60.	4.7	29
281	Controlled ten-day antimicrobial therapy in asymptomatic bacteriuria of old age: relations with localization, mobility and mortality. <i>Geriatric Nephrology and Urology</i> , 1994, 4, 137-143.	0.3	6
282	Release of Newer Quinolones from Acrylic Bone Cement and Fibrin Clots In Vitro. <i>Drugs</i> , 1993, 45, 240-241.	10.9	1
283	The Influence of Acetazolamide on Ciprofloxacin and Pefloxacin Pharmacokinetics in Human Aqueous Humour. <i>Drugs</i> , 1993, 45, 314-315.	10.9	0
284	Oral Pefloxacin and Ofloxacin in the Treatment of Malignant External Otitis. <i>Drugs</i> , 1993, 45, 320-321.	10.9	1
285	Discussion of A. R. Ronald's et al. presentation. <i>Infection</i> , 1992, 20, S178-S178.	4.7	0
286	Three-day antibiotic therapy in bacteriuria of old age. <i>Journal of Antimicrobial Chemotherapy</i> , 1990, 26, 705-711.	3.0	14
287	Enhanced in-vitro bactericidal activity of amikacin combined with latamoxef, cefotaxime and aztreonam against multi-resistant <i>Enterobacter cloacae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1989, 23, 537-545.	3.0	3
288	Preoperative Therapeutic Considerations in Chronic Suppurative Otitis Media. <i>Laryngoscope</i> , 1989, 99, 655-659.	2.0	25

#	ARTICLE	IF	CITATIONS
289	Pharmacokinetics of three newer quinolones in pregnant and lactating women. American Journal of Medicine, 1989, 87, S49-S51.	1.5	119
290	Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections. European Journal of Clinical Microbiology and Infectious Diseases, 1988, 7, 130-134.	2.9	26
291	Surveillance study of resistance in Haemophilus species in Greece. European Journal of Clinical Microbiology and Infectious Diseases, 1988, 7, 186-188.	2.9	8
292	Efficacy and Tolerance of Oral Ofloxacin in Treating Various Infections. Drugs, 1987, 34, 119-123.	10.9	2
293	Aminoglycosides plus beta-lactams against gram-negative organisms: Evaluation of in vitro synergy and chemical interactions. American Journal of Medicine, 1986, 80, 126-137.	1.5	133
294	Efficacy of Sulbactam plus Ampicillin in Gynecologic Infections. Clinical Infectious Diseases, 1986, 8, S579-S582.	5.8	11
295	Antibody-coated bacteria in urine: when, where and why?. Journal of Antimicrobial Chemotherapy, 1984, 13, 95-99.	3.0	10
296	A comparison of the Api-10M commercial microdilution system with the tube dilution and standard microdilution methods. Infection, 1984, 12, 68-71.	4.7	0
297	Rifaprim in urinary tract infection: A comparison with co-trimoxazole. Journal of Antimicrobial Chemotherapy, 1983, 11, 239-244.	3.0	2
298	A study of cefoxitin, moxalactam, and ceftazidime kinetics in pregnancy. American Journal of Obstetrics and Gynecology, 1983, 147, 914-919.	1.3	19
299	Ornidazole as a single drug in the treatment of mixed aerobic-anaerobic infections. Journal of Antimicrobial Chemotherapy, 1981, 7, 569-574.	3.0	4
300	Methicillin resistant Staphylococcus aureus infections during 1978-79: clinical and bacteriologic observations. Journal of Antimicrobial Chemotherapy, 1981, 7, 649-655.	3.0	31
301	Prospective comparative evaluation of gentamicin or gentamicin plus cephalothin in the production of nephrotoxicity in man. Journal of Antimicrobial Chemotherapy, 1979, 5, 581-590.	3.0	14
302	Cefuroxime: antimicrobial activity, human pharmacokinetics and therapeutic efficacy. Journal of Antimicrobial Chemotherapy, 1977, 3, 555-562.	3.0	22
303	Antibacterial Activity of Cinoxacin In Vitro. Antimicrobial Agents and Chemotherapy, 1975, 7, 688-692.	3.2	39
304	AMYLOIDOSIS COMPLICATING STILL'S DISEASE. Lancet, The, 1971, 297, 348.	18.7	1